Literature DB >> 8400344

Immunological quantitation of thymidylate synthase-FdUMP-5,10-methylenetetrahydrofolate ternary complex with the monoclonal antibody TS 106.

J C Drake1, C J Allegra, P G Johnston.   

Abstract

Thymidylate synthase (TS) is responsible for the conversion of deoxyuridine monophosphate to deoxythymidine monophosphate. One of the principal mechanisms of action of 5-fluorouracil (5-FU) is the inhibition of TS by formation of a ternary covalent complex consisting of TS-5-fluorodeoxyuridylate-5,10-methylenetetrahydrofolate. We have developed a Western immunoblot assay using the monoclonal antibody TS 106 to measure ternary complex and free TS in intact human carcinoma cells following exposure to either 5-FU alone or 5-FU plus leucovorin. Lysates from cells treated with either 5-FU or 5-FU/leucovorin were resolved in 15% polyacrylamide gel, transferred onto nitrocellulose and immunoblotted using TS 106 antibody. Detection of positive bands was by a chromogenic substrate strain. Immunoblotting detected free TS at 36 kDa and TS in ternary complex at 38.5 kDa which were quantitated by densitometric scanning. This assay was able to detect a ternary complex from intact cells treated with 5-FU or 5-FU/leucovorin up to 96 h after drug removal. The ratio of complex to free TS was up to 2-fold greater in 5-FU/leucovorin-treated cells compared to those treated with 5-FU alone. This assay may be applied to measuring the formation and stability of ternary complex and free TS in patient tissue samples.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8400344     DOI: 10.1097/00001813-199308000-00002

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  15 in total

1.  Effect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthase.

Authors:  Hiroaki Tsujimoto; Sayaka Tsukioka; Satoru Ono; Etsuko Sakamoto; Kazuki Sakamoto; Kohji Tsuta; Fumio Nakagawa; Hitoshi Saito; Junji Uchida; Mamoru Kiniwa; Masakazu Fukushima
Journal:  Oncol Lett       Date:  2010-09-17       Impact factor: 2.967

2.  Are we systematically under-dosing patients with fluorouracil?

Authors:  Kalpesh Patel; Christine A Iacobuzio-Donahue; Paul E Gormley; Scott E Kern; Steven C Cunningham
Journal:  J Clin Oncol       Date:  2014-03-10       Impact factor: 44.544

3.  5FU resistance caused by reduced fluoro-deoxyuridine monophosphate and its reversal using deoxyuridine.

Authors:  Ryutaro Mori; Manabu Futamura; Toshiyuki Tanahashi; Yoshihiro Tanaka; Nobuhisha Matsuhashi; Kazuya Yamaguchi; Kazuhiro Yoshida
Journal:  Oncol Lett       Date:  2017-06-30       Impact factor: 2.967

4.  The mechanism underlying resistance to 5-fluorouracil and its reversal by the inhibition of thymidine phosphorylase in breast cancer cells.

Authors:  Ryutaro Mori; Junko Ukai; Yoshihisa Tokumaru; Yoshimi Niwa; Manabu Futamura
Journal:  Oncol Lett       Date:  2022-07-15       Impact factor: 3.111

Review 5.  Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?

Authors:  Shayna L Showalter; Timothy N Showalter; Agnes Witkiewicz; Robert Havens; Eugene P Kennedy; Tomas Hucl; Scott E Kern; Charles J Yeo; Jonathan R Brody
Journal:  Cancer Biol Ther       Date:  2008-04-21       Impact factor: 4.742

6.  Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence.

Authors:  Jonathan R Brody; Tomas Hucl; Christina L Costantino; James R Eshleman; Eike Gallmeier; Heng Zhu; Michiel S van der Heijden; Jordan M Winter; Agnieszka K Wikiewicz; Charles J Yeo; Scott E Kern
Journal:  Cancer Res       Date:  2009-01-20       Impact factor: 12.701

7.  Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines.

Authors:  Tomonari Suetsugu; Ryutaro Mori; Manabu Futamura; Masahiro Fukada; Hideharu Tanaka; Itaru Yasufuku; Yuta Sato; Yoshinori Iwata; Takeharu Imai; Hisashi Imai; Yoshihiro Tanaka; Naoki Okumura; Nobuhisa Matsuhashi; Takao Takahashi; Kazuhiro Yoshida
Journal:  Oncol Rep       Date:  2021-03-02       Impact factor: 3.906

8.  A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing.

Authors:  Kalpesh Patel; Sashidhar R Yerram; Nilofer A Azad; Scott E Kern
Journal:  Oncotarget       Date:  2012-07

9.  AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition.

Authors:  William H Gmeiner; Jonathan R Brody; Alex O Haber; Aditi Jain; Chinnadurai Mani; Avinoam Nevler; Lebaron C Agostini; Talia Golan; Komaraiah Palle; Charles J Yeo
Journal:  Mol Cancer Res       Date:  2021-02-16       Impact factor: 6.333

10.  The effect of dose and interval between 5-fluorouracil and leucovorin on the formation of thymidylate synthase ternary complex in human cancer cells.

Authors:  J C Drake; D M Voeller; C J Allegra; P G Johnston
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.